Medtronic (NYSE:MDT) today released data from an independent study of its Resolute Onyx drug-eluting stent, touting strong early vessel healing at one month in a patient population with a high percentage of patients with complex coronary artery disease.
Data from the study was presented at the EuroPCR Annual Meeting in Paris, the Fridley, Minn.-based company said.
